S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Will This Be the Worst U.S. Crisis Ever? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Will This Be the Worst U.S. Crisis Ever? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Will This Be the Worst U.S. Crisis Ever? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Will This Be the Worst U.S. Crisis Ever? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Will This Be the Worst U.S. Crisis Ever? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Will This Be the Worst U.S. Crisis Ever? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Will This Be the Worst U.S. Crisis Ever? (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Will This Be the Worst U.S. Crisis Ever? (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
A Full Year Of Recommended Stock Picks Now 60% Off (Ad)
NASDAQ:CALA

Calithera Biosciences - CALA Stock Forecast, Price & News

$3.99
-0.08 (-1.97%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.84
$4.17
50-Day Range
$2.41
$55.00
52-Week Range
$2.30
$49.80
Volume
98,772 shs
Average Volume
122,142 shs
Market Capitalization
$19.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

Calithera Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
777.2% Upside
$35.00 Price Target
Short Interest
Healthy
3.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($11.70) to ($7.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

471st out of 1,293 stocks

Pharmaceutical Preparations Industry

217th out of 619 stocks

CALA stock logo

About Calithera Biosciences (NASDAQ:CALA) Stock

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Calithera Biosciences Trading Down 2.0 %

CALA Stock opened at $3.99 on Tuesday. Calithera Biosciences has a 1 year low of $2.30 and a 1 year high of $49.80. The company has a fifty day simple moving average of $4.20 and a 200 day simple moving average of $6.54. The firm has a market cap of $19.40 million, a PE ratio of -0.14 and a beta of 1.87.

Calithera Biosciences (NASDAQ:CALA - Get Rating) last released its earnings results on Tuesday, May 10th. The biotechnology company reported ($3.60) earnings per share for the quarter, missing analysts' consensus estimates of ($3.40) by ($0.20). During the same period in the previous year, the business earned ($5.60) EPS. As a group, analysts forecast that Calithera Biosciences will post -11.7 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CALA shares. LADENBURG THALM/SH SH decreased their target price on shares of Calithera Biosciences from $60.00 to $30.00 in a research note on Wednesday, May 11th. StockNews.com initiated coverage on shares of Calithera Biosciences in a research note on Tuesday, June 21st. They issued a "hold" rating for the company. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Calithera Biosciences has a consensus rating of "Hold" and a consensus target price of $50.00.

Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Stock News Headlines

What is a Reverse Stock Split and How Does it Work?
Calithera Biosciences Q1 2022 Earnings Preview
Calithera stock falls 11% as Q4 net loss widens Y/Y
See More Headlines
Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Company Calendar

Last Earnings
5/10/2022
Today
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+1,153.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-115,090,000.00
Pretax Margin
-1,113.11%

Debt

Sales & Book Value

Annual Sales
$9.75 million
Book Value
$2.17 per share

Miscellaneous

Free Float
4,541,000
Market Cap
$19.39 million
Optionable
Optionable
Beta
1.87

Key Executives

  • Dr. Susan M. Molineaux Ph.D. (Age 68)
    Founder, CEO, Pres & Director
    Comp: $923.21k
  • Ms. Stephanie Wong (Age 48)
    CFO & Sec.
    Comp: $616.4k
  • Dr. Eric B. Sjogren (Age 65)
    Sr. VP of Drug Discovery
    Comp: $579.13k
  • Dr. Christopher J. Molineaux Ph.D. (Age 69)
    Sr. VP of Devel.
  • Mr. Frank Parlati Ph.D. (Age 53)
    Sr. VP of Research
  • Dr. Emil T. Kuriakose M.D. (Age 42)
    Chief Medical Officer
  • Dr. Susan B. Demo Ph.D.
    Sr. VP of R&D Operations
  • Dr. Allison Dillon Ph.D.
    Sr. VP of Commercial & Portfolio Strategy













CALA Stock - Frequently Asked Questions

Should I buy or sell Calithera Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CALA shares.
View CALA analyst ratings
or view top-rated stocks.

What is Calithera Biosciences' stock price forecast for 2022?

4 brokerages have issued 12 month price objectives for Calithera Biosciences' stock. Their CALA share price forecasts range from $30.00 to $40.00. On average, they expect the company's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 777.2% from the stock's current price.
View analysts price targets for CALA
or view top-rated stocks among Wall Street analysts.

How has Calithera Biosciences' stock price performed in 2022?

Calithera Biosciences' stock was trading at $13.30 at the beginning of 2022. Since then, CALA stock has decreased by 70.0% and is now trading at $3.99.
View the best growth stocks for 2022 here
.

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a drop in short interest in July. As of July 15th, there was short interest totaling 144,200 shares, a drop of 27.2% from the June 30th total of 198,100 shares. Based on an average trading volume of 174,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 3.2% of the shares of the stock are sold short.
View Calithera Biosciences' Short Interest
.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our CALA earnings forecast
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating analysts' consensus estimates of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. During the same period last year, the firm earned ($6.40) EPS.

When did Calithera Biosciences' stock split?

Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include TSP Capital Management Group LLC (1.10%) and Tarbox Family Office Inc. (0.21%). Insiders that own company stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong, Susan Molineaux and Value Fund L P Biotechnology.
View institutional ownership trends
.

How do I buy shares of Calithera Biosciences?

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $3.99.

How much money does Calithera Biosciences make?

Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $19.40 million and generates $9.75 million in revenue each year. The biotechnology company earns $-115,090,000.00 in net income (profit) each year or ($28.80) on an earnings per share basis.

How many employees does Calithera Biosciences have?

Calithera Biosciences employs 92 workers across the globe.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com.

This page (NASDAQ:CALA) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.